EN3-5. Adjuvant Osimertinib vs Placebo in Resected Stg IA2-IA3 EGFRm NSCLC : global Phase III ADAURA2 Study von Yasuhiro Tsutani, Jonathan W.Goldman, Sanja Dacic, Yasushi Yatabe, Margarita Majem, Xiangning Huang, Allen Chen, Toon van der Gronde, Jie He

Volltext

EN3-4. Osimertinib adjuvant therapy in resected EGFR-mutated stage IB-IIIA NSCLC : updated ADAURA results von Masahiro Tsuboi, Yi-Long Wu, Christian Grohe, Thomas John, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W.Goldman, Sang-We Kim, Chong-Jen Yu, Huu Vinh Vu, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Frances A.Shepherd, Damien Urban, Marta Stachowiak, Ana Bolanos, Xiangning Huang, Roy S.Herbst

Volltext